Incorporating parotid gland inhomogeneity into head-and-neck treatment optimization through the use of artificial base plans

Caleb M. Sample1,2 | Jonn Wu3,4 | Steven Thomas1 | Haley Clark5

1Department of Medical Physics, BC Cancer Agency, Vancouver, BC, Canada
2Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada
3Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada
4Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
5Department of Medical Physics, BC Cancer Agency, Surrey, BC, Canada

Abstract
Despite a great improvement in target volume dose conformality made possible in recent years by modulated therapies, xerostomia remains a common and severe side effect for head-and-neck radiotherapy patients. It is known that parotid glands exhibit a spatially varying dose response; however, the relative importance of subregions throughout the entire gland has yet to be incorporated into treatment plan optimization, with the current standard being to minimize the mean dose to whole parotid glands. The relative importance of regions within contralateral parotid glands has been recently quantified, creating an opportunity for the development of a method for including this data in plan optimization. We present a universal and straightforward approach for imposing varying sub-parotid gland dose constraints during inverse treatment planning by using patient-specific artificial base plans to penalize dose deposited in sensitive regions. In this work, the proposed method of optimization is demonstrated to reduce dose to regions of high relative importance throughout contralateral parotids and improve predictions for stimulated saliva output at 1-year post-radiotherapy. This method may also be applied to impose varying dose constraints to other organs-at-risk for which regional importance data exists.

KEY WORDS
base plan, constraint, head-and-neck, parotid, radiotherapy, xerostomia

1 INTRODUCTION

Intensity-modulated radiotherapy (IMRT) has proven to be one of the most important advances in oncology in recent years, allowing a significantly higher precision of target volume dose conformality to be achieved in radiotherapy. However, parotid-sparing IMRT alone is inadequate for complete sparing of salivary function, and it remains common for head-and-neck RT (radiotherapy) patients to be burdened by a severe loss in saliva production following treatment. Head-and-neck target volumes commonly exist adjacent to or overlapping with the parotid and submandibular glands, which along with sharp dose gradients and setup error, results in dose to salivary glands being probable during head-and-neck radiation treatment. Xerostomia (subjectively dry mouth) and hyposalivation (impaired salivary flow) significantly impact one’s quality of life by crippling common abilities such as speech, chewing, swallowing, or tasting, while also causing oral infections, dental caries, and other oral sequela. Radiation to the parotid gland is the greatest risk factor for post-treatment xerostomia. The ability of intensity-modulated therapy treatment planning to attenuate the risk of xerostomia is dependent on what parotid gland dose constraints are passed to the optimizer. A constraint on the
whole-mean dose is effectual for preserving an OAR (organ-at-risk) which exhibits a pure parallel functional architecture, given that the spatial variance of dose within the OAR is unimportant. The parotid gland was once believed to exhibit a pure parallel architecture and hence a spatially homogenous dose response,\textsuperscript{12} and to this day, the current standard of care for minimizing the risk of post-RT xerostomia incidence for head-and-neck patients is to constrain the whole-gland mean dose.\textsuperscript{13} However, recent preclinical studies have demonstrated radiosensitivity within parotid glands to be inhomogeneous, having a spatially varying dose response throughout.\textsuperscript{14–18}

In a recent study, a model including voxel dose data as well as patient demographic and clinical pathology features\textsuperscript{14} found the superior–anterior portion of the parotid gland to be the most influential in predicting xerostomia recovery. Furthermore, it was found that patients who developed xerostomia had a much higher mean dose to the inferior portion of the parotid gland.\textsuperscript{14} Another study\textsuperscript{15} used a tenfold cross validation test to show that dose to the region of the parotid gland containing stem/progenitor cells around the first branching of the Stensen’s duct, was more predictive of xerostomia at 1 yr than dose to any other subregion of the gland. The same study also showed that the spatial distribution of dose in rat parotid glands affected salivary function recovery after treatment. Dose to the cranial 50% of the gland resulted in more than a 50% loss in salivary output, as well as tissue degeneration throughout the entire gland.

Clark et al.\textsuperscript{16} partitioned contralateral parotid glands (CPGs) for a single cohort of 332 patients into 2, 3, 4, 18, and 96 equal volume subsegments and derived the relative importance of each from mean dose regressors using random forests and conditional inference trees. The parotid gland with the lowest mean dose was defined as the CPG. Parotid gland structure sets and dose profiles were used to calculate the mean dose to various subsegments, and outcomes were described using stimulated saliva output at 1-yr post-RT and self-assessed xerostomia questionnaires. For 18 subsegments, the most important subsegment (caudal–anterior) had a relative importance of 3.85 times the expected result for a homogenous parotid gland. The least important subregion exhibited virtually no importance.\textsuperscript{16}

Clark et al.’s model was chosen to be used for implementing spatially varying dose constraints for multiple reasons. For one, it is the only available model that maps out relative importance values throughout the entire gland. Furthermore, it derives importance data within the original reference frame of the parotid gland without transforming to an alternate reference frame. Subsegmentation into 18 equal volume subsegments of CPGs creates a desirable size for varying constraints, as it is large enough for dose to be effectively steered, while small enough to account for the varying importance within the gland.

The spatial inhomogeneity of the dose response within the parotid gland, if incorporated into external beam RT treatment planning, could reduce the risk of xerostomia for head-and-neck patients. Studies have concluded that incorporation of nonhomogeneous effects into treatment planning can lead to improved outcomes.\textsuperscript{19,20}

The purpose of this work is to demonstrate the feasibility of a simple technique for including sub-parotid gland importance data into RT treatment plan optimization using artificial base plans (BPs). To demonstrate the technique, we used Clark et al.’s\textsuperscript{16} intra-parotid gland importance data.

## 2 MATERIALS AND METHOD

The RapidArc\textsuperscript{TM} optimizer in Varian Eclipse\textsuperscript{TM} (Varian Medical Systems, Inc.) is equipped with the ability to incorporate earlier radiotherapy deliveries into optimization. Pre-existing spatial dose distributions can be loaded directly in as BPs during optimization, and the standard optimization workflow proceeds otherwise unaltered. We made use of this feature to apply a spatially varying dose constraint to the parotid gland to preferentially spare regions of high relative importance from excessive dose during radiotherapy.

The radiotherapy structure set object of the DICOM standard files (DICOM-RTISTRUCT) for 15 retrospective head-and-neck VMAT patients was exported from the ARIA\textsuperscript{®} Oncology Information database (primary tumor site: 5 tonsil, 4 tongue, 3 base of tongue, 1 nasopharynx, 1 thyroid, 1 left neck; prescription dose: 14 70 Gy/35 fractions, 1 60 Gy/25 fractions). Each patient received a single fractionation scheme using a simultaneous integrated boost. Sex and age statistics for the cohort were unknown as patients were previously anonymized. The median volume of primary PTVs was 181.5 cc (maximum: 295.1 cc, minimum: 30.18 cc). CPGs were defined as the parotid gland having the lowest mean dose in the original treatment plan for each patient and were subsegmented into 18 equal volume regions using DICOMautomaton.\textsuperscript{21} The average minimum distance between the primary PTV and the CPG was 3.3 cm. The relative importance of all 18 subsegments was determined using Clark et al.’s population-level importance data.\textsuperscript{16} Subsegments were labeled in order of decreasing relative importance as $S_1 \rightarrow S_{18}$, where $S_1$ is the subsegment of highest relative importance. A subsegment CPG is shown labeled in Fig. 1.

DICOMautomaton was used to create artificial dose distributions (base plans) for each patient which adhered to the following formula:

1. Dose to all voxels located outside the CPG is zero.
2. Dose to regions of overlap between the CPG and target volumes is zero. This ensures that the prescription dose and tumor coverage will not be impacted.
3. Within each subsegment of the CPG, the dose is uniform
4. Dose to the region of highest relative importance (caudal-anterior, Fig. 1 was $D_0$, and the dose to other subregions was $D_0/I$, where $I$ is a scaling factor proportional to the relative importance of the region compared to the most important subregion.

Five different types of BPs were created for each patient. $D_0$ was set to 10 Gy, 20 Gy, and 30 Gy to create distributions with a linear scale $I$, and these BPs were named BP$_{10}$, BP$_{20}$, and BP$_{30}$, respectively. The values of $D_0$ were chosen as they span the range of typical mean parotid gland doses, and having multiple values allows
us to empirically determine which type of base plan is most effective for applying constraints. In addition to the three BPs mentioned, a fourth was identical to BP20 for subsegments $S_1 \rightarrow S_5$, while the dose to all other subsegments ($S_6 \rightarrow S_{18}$) were zeroed; a fifth was assigned 50 Gy to subsegments $S_1 \rightarrow S_5$, and 0 Gy to all other subsegments. These two plans were named BP20,5 and BPtop5.

In Varian Eclipse™, each patient had five placeholder plans created for the five artificially constructed BPs that were imported for use in External Beam Planning. As a control, VMAT plans were retroactively optimized while adhering to standard clinical head-and-neck protocols (both parotids whole mean < 25 Gy or 1 parotid whole mean < 20 Gy). For each patient, two arcs with opposite direction 360° gantry rotations and a difference of 60° in collimator rotation (30° and 330°) were used. Plans were then reoptimized using each artificial BP. Loading the BPs into the optimizer does not by itself implement a spatially varying dose constraint throughout the CPG, as the standard parotid dose constraint is on the whole-mean dose. Therefore, an additional upper bound dose constraint must be placed on the CPG. This constraint, combined with the BP dose, provides a spatially varying dose constraint which preferentially restricts dose to subsegments of high relative importance. The ideal constraint to set depends on the individual anatomy of the patient and was chosen to be between 0 and 15 Gy over the maximum dose in the current BP. In this manner, the constraint imposed on a given region of the CPG has varying strength, depending on the region’s dose in the BP. All clinical dose constraints were met for all plans. These plans are named P10, P20, P30, P20,5, and Ptop5, corresponding to the use of BP10, BP20, BP30, BP20,5, and BPtop5.

To maximize validity of a comparison between different plan types, it was paramount to minimize interplan bias and dose variability within structures other than the CPG. All plans for a given patient were optimized toward approximately the same V98 (percent volume receiving at least 98% of the prescription dose) in the closest PTV to the CPG. Dose constraints to other OARS for any given patient were optimized according to clinical guidelines and were independent of plan type, and PTV coverage was adjusted minimally. Doses to all OARS without PTV overlap were kept below the standard clinical constraints. Each plan for a given patient had the same constraint on the whole-mean dose of the CPG, and plans using BPs which had an upper bound constraint all had the same $D_{\text{max}} - D_0$. For example, if $P_{10}$ had the constraint $D_{\text{max}} < 20$ Gy, then $P_{20}$ had the constraint $D_{\text{max}} < 30$ Gy. These constraints remained constant throughout the course of optimization.

A C# console application for calculating mean dose to subsegments and exporting data was developed and tested to create a plug-in script that can run through the Eclipse™ Scripting API in Varian Eclipse™. A MATLAB script was then created to analyze parotid gland subsegment and other structure doses for the 15-6 = 90 plans.

Mean subsegment dose reductions between plans optimized with BPs were quantified and compared to determine which BP was most effective, and if significant reductions in mean dose to critical regions occurred. Dose to all patient structures for each plan was evaluated to ensure that all clinical dose constraints were met, and to determine if the use of BPs significantly altered mean or maximum doses to other structures. Significance was assessed at $P = 0.05$ with a paired t test. Mean subsegment doses for each plan were passed as parameters into a predictive model for stimulated salivary output at 1yr relative to baseline adapted from Clark et al.¹⁶ To reduce noise in the model, a dose response curve (Hill Model²²) was generated for each individual subsegment using the method of least squares. Curves were fit to data points obtained by incrementing dose to each subsegment from 0 by 2 Gy to 40 Gy while keeping all other subsegment doses constant. A final predictive model of the form

![Figure 1](image-url)

**Fig. 1.** Subsegments of contralateral parotid glands have varying relative importance for predicting post-RT xerostomia.¹⁶ Here, the spatial distribution of importance is illustrated from (a) the anterior, and (b) the posterior. Subsegments are labeled according to their importance in (c).

SAMPLE ET AL. | 143

WILEY
was created, where $D_i$ is the dose to subsegment $S_i$, $\Delta_i$ is the maximum loss in salivary output predicted by infinite dose to $S_1$ independently, and $D_{50}$, $n$ are parameters fit to the data, representing the dose predicting a decline in salivary output of $\frac{1}{2}\Delta_i$, and the steepness of the curve. The predicted response when only dose to $S_1$ is considered (Eq. (1) with only $i = 1$) is shown in Fig. 2.

### 3 | RESULTS

Within the CPG, the mean dose to all subsegments is shown for each plan type in Table 1 with statistically significant dose differences indicated. $P_{\text{top5}}$ showed the greatest reduction to the mean dose of $S_1$ ($M = 8.6$ Gy, SD = 3.9 Gy), $t(14) = 8.62$, $P < 0.001$, followed closely by $P_{30}$ ($M = 8.1$ Gy, SD = 3.7 Gy), $t(14) = 8.45$, $P < 0.001$. All plans reduced the whole mean dose of the CPG significantly, with the greatest reduction seen with $P_{20}$ ($M = 2.1$ Gy, SD = 1.2 Gy), $t(14) = 6.60$, $P < 0.001$, followed by $P_{20}$ ($M = 2.0$ Gy, SD = 1.0 Gy), $t(14) = 7.68$, $P < 0.001$. In general, dose to parotid gland subsegments of high relative importance, which tends toward the caudal end of the gland, was reduced when planning with BPs as seen in Fig. 3. $P_{20}$, $P_{30}$, and $P_{\text{top5}}$ significantly reduced dose to the

### Table 1

| Subsegment | Plan type | Mean dose (Gy) |
|------------|-----------|----------------|
|            |           | $P_0$ | $P_{10}$ | $P_{20}$ | $P_{30}$ | $P_{20,5}$ | $P_{\text{top5}}$ |
| $S_1$      |           | 27.8  | 22.3  | 20.9*   | 19.8*   | 20.7*    | 19.2*       |
| $S_2$      |           | 11.1  | 10.9  | 9.9*    | 10.0*   | 10.9     | 10.0*       |
| $S_3$      |           | 29.6  | 24.6* | 23.8*   | 23.3*   | 23.4*    | 21.5*       |
| $S_4$      |           | 40.2  | 36.2* | 35.5*   | 34.7*   | 35.2*    | 33.2*       |
| $S_5$      |           | 18.3  | 15.7* | 14.6*   | 14.2*   | 14.8*    | 13.5*       |
| $S_6$      |           | 22.3  | 21.5* | 20.8*   | 20.9*   | 22.6     | 22.8        |
| $S_7$      |           | 8.3   | 8.3   | 8.2     | 8.3     | 9.0      | 9.4         |
| $S_8$      |           | 40.8  | 37.2* | 36.8*   | 36.3*   | 36.9*    | 35.5*       |
| $S_9$      |           | 10.2  | 10.0  | 9.5     | 9.7     | 10.4     | 10.1        |
| $S_{10}$   |           | 20.9  | 17.7* | 17.2*   | 17.1*   | 17.4*    | 15.6*       |
| $S_{11}$   |           | 6.5   | 6.5   | 6.4     | 6.6     | 7.0      | 7.1         |
| $S_{12}$   |           | 5.9   | 5.97  | 5.8     | 6.0     | 6.4      | 6.6         |
| $S_{13}$   |           | 7.8   | 7.7   | 7.8     | 7.9     | 8.45     | 9.0*        |
| $S_{14}$   |           | 12.6  | 12.3  | 12.8    | 12.7    | 13.5     | 14.6*       |
| $S_{15}$   |           | 12.4  | 12.1  | 11.7    | 11.8    | 12.6     | 13.3        |
| $S_{16}$   |           | 15.7  | 15.0* | 14.7*   | 14.9    | 15.8     | 17.2*       |
| $S_{17}$   |           | 6.8   | 6.8   | 6.9     | 6.8     | 7.4      | 7.9*        |
| $S_{18}$   |           | 25.3  | 24.5* | 25.0    | 25.1    | 26.0     | 27.8*       |
| Whole gland|           | 18.3  | 16.7* | 16.3*   | 16.2*   | 16.8*    | 16.6*       |

*Significant difference ($P < 0.05$).

**Fig. 2.** The predicted stimulated saliva output according to the Clark et al.\textsuperscript{16} model at 1-yr post-RT relative to baseline is shown for subsegment $S_1$. 
The top five most important subsegments of the CPG, while P10 and P20.5 insignificantly reduced dose to S2. The mean dose received by each subsegment of the CPG in each plan type is listed in Table 1. Ptop5 significantly increased dose to several subsegments of low relative importance (S_{13}, S_{14}, S_{16}, S_{17}, S_{18}).

All plans optimized with BPs demonstrated statistically significant improvements in stimulated saliva predictions at 1-year post-RT. Optimizing with BPs resulted in up to a 23% improvement in predicted saliva output (mean = 18%) as compared to optimizing without BPs, as shown in Table 2. BP_{30} and BP_{top5} demonstrated the greatest improvements in salivary output, while BP_{10} resulted in the smallest improvement (13%). One patient’s dose distribution in the middle of the CPG is shown for each type of plan in Fig. 4.

The mean overlap percentage of CPGs with target volumes was 13.7% (median 13%, maximum 33%), and subsegments along the

| Plan type | Saliva output (fraction of baseline) | Improvement from P_0 (%) | Absolute saliva output increase (%) | Statistical significance |
|-----------|-------------------------------------|--------------------------|-------------------------------------|-------------------------|
| P_0       | 0.48                                | N/A                      | N/A                                 | N/A                     |
| P_{10}    | 0.54                                | 13                       | 6                                   | t(14) = 3.1, P < 0.01   |
| P_{20}    | 0.57                                | 19                       | 9                                   | t(14) = 5.3, P < 0.001  |
| P_{30}    | 0.59                                | 23                       | 11                                  | t(14) = 4.7, P < 0.001  |
| P_{20.5}  | 0.55                                | 15                       | 7                                   | t(14) = 2.9, P < 0.02   |
| P_{top5}  | 0.59                                | 23                       | 11                                  | t(14) = 4.0, P < 0.002  |
caudal–medial portion of glands were most prone to overlap. The frequency of overlapping for various subsegments is summarized in Table 3.

Optimizing with BPs did not prevent clinical dose constraints for OARs or target volumes from being adhered to. Primary and secondary PTVs had no apparent trend toward decreased or increased dose coverage with base plans. The cumulative DVH for one patient’s primary PTV is shown for all different plan types in Fig. 5. Submandibular glands had extensive overlap with target volumes in all 15 patients, making it impossible for them to be spared from high dose without subsequent reductions in dose to target volumes. Contralateral submandibular gland mean doses were increased with statistical significance when optimizing with BPs, with PTop5 resulting in the largest difference ($M = 1.7$ Gy, $SD = 1.5$ Gy), $t(10) = 3.86$, $P < 0.01$. Three patients’ contralateral submandibular glands were not contoured and were not included in this statistic. Mean dose to the oral cavity was also increased with statistical significance when using BPs, with the largest difference found with $P_{20}$ ($M = 1.4$ Gy, $SD = 1.7$ G).

**Table 3** The number of patients with contralateral parotid gland subsegments overlapping with planning target volumes.

| Subsegment | Number Overlapping | Subsegment | Number |
|------------|--------------------|------------|--------|
| $S_1$      | 11                 | $S_{10}$   | 4      |
| $S_2$      | 1                  | $S_{11}$   | 0      |
| $S_3$      | 11                 | $S_{12}$   | 0      |
| $S_4$      | 13                 | $S_{13}$   | 0      |
| $S_5$      | 2                  | $S_{14}$   | 4      |
| $S_6$      | 11                 | $S_{15}$   | 0      |
| $S_7$      | 4                  | $S_{16}$   | 8      |
| $S_8$      | 13                 | $S_{17}$   | 0      |
| $S_9$      | 0                  | $S_{18}$   | 11     |
| Whole gland| 13                 |            |        |

**FIG. 4.** The dose distribution for a sagittal plane slice of the CPG is shown for each different plan type created for a single patient. (a): $P_0$; (b): $P_{10}$; (c): $P_{20}$; (d): $P_{30}$; (e): $P_{	ext{Top5}}$; (f): $P_{20,5}$. The most important subsegment derived with Clark et al.’s model is located in the caudal–anterior (bottom right) portion of the gland, where isodose lines can be clearly seen to shift away from when using BPs, and particularly with $BP_{30}$ (D).

**TABLE 3** The number of patients with contralateral parotid gland subsegments overlapping with planning target volumes.

The base plan approach for incorporating various intra-parotid gland dose constraints into head-and-neck RT plans through the
use of artificially constructed dose distributions demonstrated that the optimizer can effectively steer dose away from critical regions. This method does not require creation of additional structure contours, or manipulation of unique dose constraints for the numerous subsegments, allowing the optimization workflow to proceed normally after loading the base plan and setting the one

**Fig. 5.** The cumulative dose–volume histogram for the primary PTV (a) and gross tumor volume (GTV, b) revealed no apparent trend toward decreased or increased coverage when BPs are used during optimization, as illustrated with a single representative patient.
additional constraint on the CPG. Furthermore, adding a unique dose constraint for each subsegments structure may have a noticeable impact on the optimization time.

We used population-level relative importance information of 18 equal volume parotid gland subsegments, derived from a large cohort of patients to decide upon various suborgan dose constraints to impose during optimization. This approach produced more favorable predicted patient outcomes. Predicted xerostomia risk was lowered with minimal additional effort required during treatment planning. This method improves upon the current whole-parotid approach to treatment planning by incorporating parotid dose response heterogeneity into treatment plan optimization.

That parotid gland subsegments of high relative importance showed significant reductions in dose, while less important subsegments had more modest improvements or even increases in dose, is not unexpected. Highly important subsegments had proportionally high dose constraints set so that dose could be redirected away from important regions without implementing too strict a constraint on the whole gland such that PTV coverage is compromised. Regions of high relative importance tend toward the caudal end of the CPG, where the largest reductions in mean dose were found. The extent of PTV overlap with CPGs has been shown to be correlated with patient outcomes and the base plan approach has less impact when patients have extensive overlap. CPGs were frequently found to overlap with planning target volumes in this study, with 13/15 parotid glands involving some degree of overlap. Despite this difficulty, the whole-mean dose and mean dose to important subsegments frequently found to overlap with target volumes (S1, S3, S4, S6) showed significant reductions in dose with P30.

Five different types of base plans were used to reoptimize treatment plans in this study. The two most effective plans for sparing important subsegments and improving predicted patient outcomes were P30 and Ptop5, which resulted in identical predictions for stimulated saliva output at 1-year post-RT. The fact that these were the most effective plans is unsurprising as they offer the largest variance in dose constraints within the CPGs. Ptop5 marginally outperformed P30 in terms of reducing dose to the top five most important subsegments; however, this came at the expense of statistically significant increases in dose to other parotid subsegments of low relative importance. While this is presumably a favorable trade-off, given uncertainty in the model P30 is a more moderate plan which also achieved the greatest reduction to the whole mean dose of the CPG, qualifying it as the plan adhering best to the ALARA (As Low As Reasonably Achievable) principle.

P30 is also favorable over Ptop5 as it is easier to manage within Varian Eclipse™. The base plan approach presents challenges when imposing large dose penalties, as the maximum dose contained in the base plan will contribute to the maximum body dose during optimization, which could impede the planner’s ability to determine if a dose constraint for the body is violated or not. Another subtlety which must be accounted for during optimization is a shift in the CPG mean dose constraint that occurs when using BPs. The CPG’s mean dose in the BP is absorbed into the mean dose of the gland during optimization, so the planner must shift the whole-mean dose of the CPG up by an amount equal to the mean dose within the BP. Both of these issues can be mitigated by copying the optimized fields to a new plan without BPs, but it might not immediately be clear to reviewers whether a BP has been used or is included in dose reports.

A significant reduction in dose to the top five important regions of CPGs as well as the whole mean as seen with P30 demonstrates efficacy of the proposed technique. Dose to other OARs and target volumes continued to meet clinical constraints when planning with BPs. Increases in dose to contralateral submandibular glands were not clinically significant, albeit did have statistical significance. The dose to these glands was either weakly constrained or not at all, and as a result, small increases in their already high doses had no effect on patient outcomes. Oral cavity mean doses were kept below clinical recommendations, so the statistically significant increase in mean dose seen is likely to be clinically insignificant.

The model by Clark et al. has yet to be clinically validated since it was derived. We believe it to be a valid quantitative model as saliva predictions using segmentation into 18 subregions had values for mean-absolute-error and root-mean-square-error which are comparable to values when predictions were made using whole-mean dose. Clark et al.’s model was used in our methods as it was the most favorable for designing constraints, however, the base plan method for imposing dose constraints can be applied using data from other models of regional importance for an organ at risk. The emphasis of this work is on the method of incorporating subregional dose constraints using artificial base plans that are specifically designed based on model data.

A challenge in this study was establishing a valid interplan comparison, as the varying initial dose conditions contained in each base plan ensures that optimized dose profiles for plans are nonidentical both inside and outside the CPGs. To minimize systematic errors, dose constraints to all OARs other than the CPG and all PTVs other than those in proximity to the CPG were set to the same value in different plan types, and the same V98 goal for bordering/overlapping PTVs was set in each case. Plans were created in a random order by a single planner for all patients. However, variability in the optimization process for each plan was impossible to eliminate entirely and could have impacted this study.

In the future, we wish to extend this work by imposing suborgan optimization criteria directly through the scripting API of treatment planning systems. The prospect of including dose constraints without requiring artificial base plans is appealing, but presents additional challenges as Varian Eclipse™’s scripting API requires that automatic optimization proceeds inside a separate scripting window, meaning that dose constraints must be rigidly preset by the treatment planner. On the contrary, the approach presented here allows the treatment planner full and regular access to the standard optimization window, so that constraints can be adjusted throughout the course of optimization.
5 | CONCLUSION

It is known that parotid glands exhibit an inhomogeneous dose response, and there is promise that post-treatment xerostomia outcomes can be significantly improved by incorporating this information into clinical planning workflows. A universal method for incorporating suborgan dose constraints into VMAT treatment planning has been featured as an effective means of steering dose away from important regions of the parotid gland. This method may also be applied to other OARs for which spatial importance data exist.

AUTHOR CONTRIBUTION STATEMENT

All authors were involved in designing this study. The manuscript was drafted by Caleb Sample, and critical revisions were made by Haley Clark, Jonn Wu, and Steven Thomas. Software for developing base plans and predicting saliva output was generated by Haley Clark. Treatment planning and analysis was done by Caleb Sample.

CONFLICT OF INTEREST

Caleb Sample, Jonn Wu, Steven Thomas, and Haley Clark have no conflict of interest to disclose.

REFERENCES

1. Powell TE. Intensity-modulated radiotherapy - what is it. Cancer Imaging. 2004;4(2):68–73. https://doi.org/10.1102/1470-7330.2004.0003.
2. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84:967–996.
3. Kam MKM, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873–4879.
4. Ma SJ, Rivers C, Serra LM, Singh AK. Long-term outcomes of interventions for radiation-induced xerostomia: a review. World J Clin Oncol. 2019;10:1–13.
5. Cheng SCH, Wu VWC, Kwong DLW, Yung TC. Assessment of post-radiotherapy salivary glands. Br J Radiol. 2011;84:393–402.
6. Lee C, Langen KM, Lu W, et al. Assessment of parotid gland dose changes during head and neck cancer radiotherapy using daily mega-voltage computed tomography and deformable image registration. Int J Radiat Oncol Biol Phys. 2008;71:1563–1571.
7. Cassolato S, Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology. 2004;20:64–77.
8. Pedersen AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis. 2002;8:117–129.
9. Ekstrom J, Khosravani N, Castagnola M, Messana I. Saliva and the control of its secretion. In: Treatment Dda, ed. O Ekberg. Berlin: Springer-Verlag; 2012. https://doi.org/10.1007/174_2011_481.
10. Villa A, Polimeni A, Strohmenger L, Cicciu D, Gherlone E, Abati S. Dental patients’ self-reports of xerostomy and associated risk factors. J Am Dent Assoc. 2011;142:811–816.
11. Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia. Head Neck. 2007;29:58–63.
12. Eisbruch A, Ship JA, Hyungjin MK, Ten Haken RK. Partial irradiation of the parotid gland. Semin Radiat Oncol. 2001;11:234–239.
13. Deasy JO, Moiseenko V, Marks L, Clifford Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76:558–563.
14. Jiang W, Lakshminarayanan P, Hui Z, et al. Machine learning methods uncover radiomorphologic dose patterns in salivary glands that predict xerostomia in patients with head and neck cancer. Adv Radiat Oncol. 2019;4:401–412.
15. van Luijk P, Pringle S, Deasy JO, et al. Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer. Sci Transl Med. 2015;7:305ra147.
16. Clark HD, Thomas SD, Reinsberg SA, Moiseenko VV, Hovan AJ, Wu JS. Heterogeneous radiotherapy dose-outcomes response. Converg Sci Phys Oncol. 2018;4:035001.
17. Konings A, Cottelee F, Faber H, Van Luijk P, Meertens H. Volume effects and region-dependent radiosensitivity of the parotid gland. J Radiat Oncol. 2005;62:1090–1095.
18. Buettner F, Miah A, Gulliford S, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2012;103:82–87.
19. Miah AB, Gulliford SL, Morden J, et al. Recovery of salivary function: contralateral parotid-sparing intensity-modulated radiotherapy versus bilateral superficial lobe parotid-sparing intensity-modulated radiotherapy. Clin Oncol. 2016;28:e69–e76.
20. Xiao W, Lin Z, Zhang W, Li M, Wu V. A split-parotid delineation approach for dose optimization in volumetric modulated arc therapy for nasopharyngeal carcinoma patients with parapharyngeal space invasion and level IIA cervical lymph node involvements. Br J Radiol. 2016;89:20150635.
21. Clark H, Moiseenko V, Lee R, Gill B, Duzenli C, Wu J. Automated segmentation and dose-volume analysis with DICOMautomaton. J Phys: Conf Ser. 2014;489:012009.
22. Langley JN. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol. 1910;40. https://doi.org/10.1042/1742-6596/489/1/012009.
23. Millunchick C, Zhen H, Redler G, Liao Y, Turian J. A model for predicting the dose to the parotid glands based on their relative overlapping with planning target volumes during helical radiotherapy. J Appl Clin Med Phys. 2018;19:48–53.
24. Gensheimer M, Hummel-Kramer S, Cain D, Quang T. Simple tool for prediction of parotid gland sparing in intensity-modulated radiation therapy. Med Dosim. 2015;40:232–234.
25. Hunt M, Jackson A, Narayana A, Lee N. Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. Int J Radiat Oncol Biol Phys. 2006;66:296–304.